Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Seres Therapeutics (MCRB) over the last 10 years, with Q3 2025 value amounting to $8.7 million.

  • Seres Therapeutics' Other Non-Current Assets fell 1220.5% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 1220.5%. This contributed to the annual value of $8.7 million for FY2024, which is 8632.51% down from last year.
  • Seres Therapeutics' Other Non-Current Assets amounted to $8.7 million in Q3 2025, which was down 1220.5% from $8.7 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Other Non-Current Assets peaked at $63.4 million during Q4 2023, and registered a low of $601000.0 during Q3 2021.
  • Its 5-year average for Other Non-Current Assets is $14.5 million, with a median of $9.5 million in 2022.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first soared by 181980.03% in 2022, then crashed by 8632.51% in 2024.
  • Seres Therapeutics' Other Non-Current Assets (Quarter) stood at $8.0 million in 2021, then surged by 30.81% to $10.5 million in 2022, then skyrocketed by 505.7% to $63.4 million in 2023, then crashed by 86.33% to $8.7 million in 2024, then changed by 0.0% to $8.7 million in 2025.
  • Its Other Non-Current Assets was $8.7 million in Q3 2025, compared to $8.7 million in Q2 2025 and $8.7 million in Q1 2025.